Document Detail


Efficacy of hormonal manipulation in lymphangioleiomyomatosis. A 20-year-experience in 36 patients.
MedLine Citation:
PMID:  18069418     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
RATIONALE: Lymphangioleiomyomatosis (LAM) is a rare disease of unknown aetiology which mainly affects women of reproductive age. A growing body of evidence suggests a relation between the disease and estrogenic hormones. In particular, pregnancy and use of estrogens favour the progression of the disease, which is in turn slowed down by menopause. These observations suggested already in the past a treatment strategy based on hormonal manipulation: discontinuation of estrogens containing medications, avoiding pregnancy, inhibition of estrogens activity and induction of menopause. OBJECTIVES: In the present study, conducted on a relatively large population for a rare disease, we sought to show the hormonal manipulation's positive effects for the survival rate. METHODS: 36 women suffering from LAM were evaluated between January 1985 and March 2005. All our patients were treated with hormonal therapy, following different schemes. The response to the treatment was evaluated in all patients with arterial blood sampling, lung function tests (total body plethysmography, DLCO), measurement of the hormones in the blood, chest and abdomen CT scan. MEASUREMENTS AND MAIN RESULTS: The survival rate since the clinical onset was 97% at the 5 year timepoint, 90% at 10 years, and 71% at 25 years. Previous studies, conducted before the introduction of the hormonal treatment showed a survival rate of 20% at 10 years. CONCLUSIONS: Our results highlight the role of the hormonal manipulation as a mainstay in the treatment of LAM, with the capability of reducing mortality and improving the quality of life as well.
Authors:
Mario Schiavina; Paola Contini; Andrea Fabiani; Franca Cinelli; Valerio Di Scioscio; Maurizio Zompatori; Cristina Campidelli; Stefano A Pileri
Related Documents :
9288368 - Analgesic effect of a herbal medicine for treatment of primary dysmenorrhea--a double-b...
9782138 - Does preoperative treatment with a gonadotropin-releasing hormone agonist improve the o...
1621528 - Combined human chorionic gonadotropin (hcg) and human menopausal gonadotropin (hmg) tre...
18259018 - Prolonged ovarian hormone deprivation impairs the protective vascular actions of estrog...
9267838 - Epilepsy and everyday life risks. a case-referent study: rationale, study design, and p...
8530228 - Perioperative benzimidazole therapy in human hydatid liver disease.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG / World Association of Sarcoidosis and Other Granulomatous Disorders     Volume:  24     ISSN:  1124-0490     ISO Abbreviation:  Sarcoidosis Vasc Diffuse Lung Dis     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-12-11     Completed Date:  2008-02-11     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9610928     Medline TA:  Sarcoidosis Vasc Diffuse Lung Dis     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  39-50     Citation Subset:  IM    
Affiliation:
Respiratory Pathophysiology Unit, S. Orsola-Malpighi Hospital, Via Massarenti 9 40138 Bologna, Italy. mschiavina@aosp.bo.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Estrogen Antagonists / administration & dosage,  therapeutic use*
Estrogens / metabolism*
Female
Hormones / administration & dosage,  therapeutic use*
Humans
Leuprolide / administration & dosage,  therapeutic use
Luteolytic Agents / administration & dosage,  therapeutic use
Lymphangioleiomyomatosis / drug therapy,  physiopathology*,  surgery,  therapy*
Medroxyprogesterone Acetate / administration & dosage,  therapeutic use
Menopause
Middle Aged
Ovariectomy
Respiratory Function Tests
Triptorelin / administration & dosage,  therapeutic use
Chemical
Reg. No./Substance:
0/Estrogen Antagonists; 0/Estrogens; 0/Hormones; 0/Luteolytic Agents; 53714-56-0/Leuprolide; 57773-63-4/Triptorelin; 71-58-9/Medroxyprogesterone Acetate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The MCP-1-2518 (A to G) single nucleotide polymorphism in Czech patients with pulmonary sarcoidosis:...
Next Document:  Bone turnover and hip bone mineral density in patients with sarcoidosis.